We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+25.27%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$474M
AUM Growth
+$94.5M
Cap. Flow
+$37.7M
Cap. Flow %
7.94%
Top 10 Hldgs %
76.63%
Holding
34
New
6
Increased
17
Reduced
4
Closed
6

Top Buys

1
PTCT icon
PTC Therapeutics
PTCT
+$26.9M
2
ABUS icon
Arbutus Biopharma
ABUS
+$12.9M
3
BMY icon
Bristol-Myers Squibb
BMY
+$11.1M
4
ACHN
Achillion Pharmaceuticals
ACHN
+$6.39M
5
OMER icon
Omeros
OMER
+$4.14M

Top Sells

1
MDCO
Medicines Co
MDCO
+$28M
2
INCY icon
Incyte
INCY
+$11M
3
IVTY
Invuity, Inc
IVTY
+$3.47M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$3.32M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$2.72M

Sector Composition

1 Healthcare 97.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNY icon
1
Alnylam Pharmaceuticals
ALNY
$37.8B
$83M 17.5%
1,040,607
-51,909
-5% -$3.32M
PTCT icon
2
PTC Therapeutics
PTCT
$6.51B
$60.6M 12.77%
3,304,214
+1,998,571
+153% +$26.9M
AVXS
3
DELISTED
AveXis, Inc. Common Stock
AVXS
$48.2M 10.17%
587,117
-36,213
-6% -$2.72M
BMY icon
4
Bristol-Myers Squibb
BMY
$124B
$43.2M 9.1%
774,675
+203,983
+36% +$11.1M
LJPC
5
DELISTED
La Jolla Pharmaceutical Company
LJPC
$33M 6.95%
1,107,379
+78,450
+8% +$2.25M
RGNX icon
6
Regenxbio
RGNX
$579M
$25.1M 5.3%
1,272,770
+56,265
+5% +$1.09M
ABUS icon
7
Arbutus Biopharma
ABUS
$936M
$18.8M 3.95%
5,209,823
+3,763,236
+260% +$12.9M
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.31B
$18.5M 3.91%
3,333,958
-124,162
-4% -$756K
AGEN
9
Agenus
AGEN
$208M
$16.7M 3.53%
217,936
+1,608
+0.7% +$113K
ATRA icon
10
Atara Biotherapeutics
ATRA
$78.6M
$16.4M 3.46%
46,910
+10,561
+29% +$4.07M
OXFD
11
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$14.2M 3%
846,917
+234,014
+38% +$3.5M
CORI
12
DELISTED
Corium International, Inc.
CORI
$12.2M 2.57%
1,632,001
+183,010
+13% +$1.09M
BLUE
13
DELISTED
bluebird bio
BLUE
$11M 2.31%
8,058
+59
+0.7% +$71.2K
TCMD icon
14
Tactile Systems Technology
TCMD
$663M
$10.6M 2.24%
372,302
+84,426
+29% +$1.9M
OSUR icon
15
OraSure Technologies
OSUR
$273M
$10.2M 2.14%
588,256
+22,026
+4% +$317K
MASI
16
DELISTED
Masimo
MASI
$9.2M 1.94%
100,900
+20,000
+25% +$1.84M
VIVE
17
DELISTED
VIVEVE MED INC
VIVE
$8.9M 1.88%
1,239
+93
+8% +$693K
ACHN
18
DELISTED
Achillion Pharmaceuticals
ACHN
$7.3M 1.54%
+1,590,454
New +$6.39M
DRNA
19
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$6.59M 1.39%
2,078,991
+16,000
+0.8% +$50.5K
VRAY
20
DELISTED
ViewRay, Inc.
VRAY
$4.95M 1.04%
764,335
+248,723
+48% +$1.67M
OMER icon
21
Omeros
OMER
$667M
$4.73M 1%
+237,453
New +$4.14M
FSTX
22
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$3.38M 0.71%
+62,500
New +$2.89M
UHS icon
23
Universal Health Services
UHS
$9.29B
$3.15M 0.66%
+25,800
New +$3.07M
PODD icon
24
Insulet
PODD
$11.4B
$2.98M 0.63%
+58,000
New +$2.52M
GBT
25
DELISTED
Global Blood Therapeutics, Inc.
GBT
$721K 0.15%
26,377
+194
+0.7% +$5.77K
1
2

Similar funds

BEI
Benjamin Edwards Inc Clayton, Missouri $10.1B AUM 14.03% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return

RTW Investments's Q2 2017 Portfolio in Review

As of Q2 2017, RTW Investments held 34 positions worth $474M, up 25% from $380M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

RTW Investments deployed $37.7M of net new capital in Q2 2017, opening 6 new positions and adding to 17 existing holdings. Its largest new stake was Achillion Pharmaceuticals: 1,590,454 shares worth $7.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 90% a quarter earlier.

On the sell side, the largest reduction was Invuity, Inc, an estimated $3.47M trimmed.

  • RTW Investments's largest Q2 2017 buy was Achillion Pharmaceuticals: 1,590,454 shares worth $7.3M.
  • RTW Investments added most to PTC Therapeutics in Q2 2017, an estimated $26.9M increase.
  • RTW Investments's biggest Q2 2017 reduction was Invuity, Inc, cutting an estimated $3.47M.
  • RTW Investments fully exited Medicines Co in Q2 2017, selling an estimated $28M.
  • RTW Investments's ten largest holdings make up 77% of its $474M portfolio in Q2 2017.
  • RTW Investments opened 6 new positions and closed 6 in Q2 2017.
  • RTW Investments's portfolio value rose 25% quarter-over-quarter to $474M.

Based on RTW Investments's 13F filing for Q2 2017, filed 14 Aug 2017.